此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Phase Ⅰ/Ⅱa Trial Evaluating Intravenous hUC-MSCs Injection for Safety, Tolerability and Efficacy in Patients With POI

2026年8月19日 更新者:Shenzhen Wingor Biotechnology Co., Ltd.

Phase Ⅰ/Ⅱa Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Injection of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in Patients With Premature Ovarian Insufficiency (POI)

A Phase I/IIa clinical study evaluating the safety, tolerability and efficacy of intravenously administered human umbilical cord mesenchymal stem cell (hUC-MSCs) injection in patients with premature ovarian insufficiency (POI).

The primary objective of the Phase I dose-escalation stage is to assess the safety and tolerability of intravenous infusion of hUC-MSCs injection for the treatment of POI, and to determine the recommended phase II dose (RP2D) for the Phase IIa clinical trial.

The primary objective of the Phase IIa dose-expansion stage is to evaluate the efficacy of intravenous infusion of hUC-MSCs injection in POI treatment, and to generate data to support pivotal/confirmatory clinical trials.

研究概览

详细说明

Premature ovarian insufficiency (POI) is defined as ovarian dysfunction occurring in women before the age of 40, which is mainly characterized by menstrual abnormalities (amenorrhea, oligomenorrhea or polymenorrhea), elevated gonadotropin levels (FSH > 25 U/L), and fluctuating decline in estrogen levels. The incidence of POI is age-specific: 1 in 250 women develops POI before 35 years of age, and 1 in 100 women develops POI before 40 years of age. The incidence rate of POI in China is 2.8%, showing an upward trend year by year with a younger onset age.

hormone replacement therapy (HRT) relieves symptoms caused by low estrogen through estrogen supplementation. Sequential estrogen-progestogen therapy is recommended for POI patients with an intact uterus. Since patients with POI require long-term HRT, natural or nearly natural estrogens and progestogens can be selected to minimize adverse effects on the mammary gland, metabolism, cardiovascular system and other systems. Nevertheless, HRT still increases the risks of breast cancer, heart disease and stroke.

Studies have demonstrated that mesenchymal stem cells can home to ovarian stroma, regulate the balance of Th1/Th2 cytokines and the expression of endometrial natural killer cells, alleviate inflammatory responses, inhibit apoptosis of ovarian granulosa cells and reduce ovarian interstitial fibrosis, thereby improving the ovarian microenvironment. Meanwhile, these cells can secrete growth factors including VEGF, IGF-1 and HGF, promote proliferation of various ovarian cells and angiogenesis, repair ovarian structure and restore ovarian ovarian function. This study aims to evaluate the safety, tolerability and efficacy of intravenously administered hUC-MSCs in the treatment of patients with POI.

研究类型

介入性

注册 (估计的)

59

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100730
        • 招聘中
        • Peking Union Medical College Hospital
        • 接触:
          • Qi Yu, Prof.
          • 电话号码:+86 10 6915 8621
          • 邮箱:yuqimd@163.com

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Aged 18 to 40 years at the time of signing the informed consent form (exclusive of the boundary values);
  2. Meet the diagnostic criteria specified in the Expert Consensus on Clinical Diagnosis and Treatment of Premature Ovarian Insufficiency (2023 Edition): oligomenorrhea (menstrual cycle longer than 35 days) or amenorrhea for more than 4 months, with basal serum follicle-stimulating hormone (FSH) > 25 U/L (tested on Days 2-4 of the menstrual cycle or during amenorrhea, at least twice with an interval of ≥4 weeks);
  3. Satisfy one of the following two criteria:

    1. Total number of antral follicles (AFC) with a diameter of 2-10 mm in bilateral ovaries < 5;
    2. Serum anti-Müllerian hormone (AMH) ≤ 7.85 pmol/L (equivalent to 1.1 ng/mL);
  4. Have received standardized hormone replacement therapy (HRT) at a stable dose for ≥3 months prior to drug administration with stable hormone levels, and maintain stable HRT per medical advice throughout the trial (within 24 weeks after enrollment);
  5. Have no fertility requirements;
  6. Agree to use effective contraceptive measures throughout the trial period (such as complete abstinence, condoms, cervical caps plus spermicides, intrauterine devices, etc.);
  7. Negative serum β-hCG test result during the screening period (to rule out pregnancy);
  8. Fully understand the trial information and sign the informed consent form.

Exclusion Criteria:

  1. Subjects with primary amenorrhea;
  2. Subjects with thyroid disorders (hypothyroidism/hyperthyroidism or thyroid malignant tumors) or resistant ovary syndrome (ROS);
  3. Subjects with abnormal female karyotypes (e.g., Turner syndrome, Fragile X syndrome);
  4. Positive serology tests (HBV antibody, HCV antibody, HIV antibody, syphilis). Exceptions: HBV carriers, patients with stable HBV after drug treatment (HBV DNA titer ≤500 IU/mL or copies <1000 copies/mL), and patients with cured HCV (negative HCV RNA test) may be enrolled if deemed eligible by the investigator;
  5. Subjects receiving or planning to use the following medications during the trial: oral or systemic corticosteroids, danazol, anticoagulants, Chinese herbal medicines or botanical supplements that may affect hormone levels or ovarian function;
  6. History of hypersensitivity to human serum albumin;
  7. Pregnant or breastfeeding subjects;
  8. Participation in another clinical trial within the past 3 months, or receipt of other cell therapies (excluding blood transfusion);
  9. History of malignant tumors;
  10. Subjects with contraindications or cautions for estrogen use, including known or suspected breast cancer, endometrial cancer, other known or suspected sex hormone-dependent malignancies, active venous or arterial thromboembolic diseases within the last 6 months, undiagnosed abnormal genital bleeding, severe hepatic or renal insufficiency [serum aspartate aminotransferase (AST) >3×ULN, serum alanine aminotransferase (ALT) >3×ULN, estimated glomerular filtration rate (eGFR) <60 mL/min], etc.;
  11. Uncontrolled diabetes, hypertension (>150/100 mmHg), heart disease, etc.;
  12. Any other conditions judged by the investigator to render the subject unsuitable for participation in this study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Phase I, Dose Cohort 1
Human Umbilical Cord Mesenchymal Stem Cells Injection
hUC-MSCs Injection, administered via intravenous infusion as a single dose on D0.
其他名称:
  • hUC-MSCs
实验性的:Phase I, Dose Cohort 2
Human Umbilical Cord Mesenchymal Stem Cells Injection
hUC-MSCs Injection, administered via intravenous infusion as a single dose on D0.
其他名称:
  • hUC-MSCs
实验性的:Phase I, Dose Cohort 3
Human Umbilical Cord Mesenchymal Stem Cells Injection
hUC-MSCs Injection, administered via intravenous infusion as a single dose on D0.
其他名称:
  • hUC-MSCs
实验性的:Phase IIa, Medium-Dose Cohort
Human Umbilical Cord Mesenchymal Stem Cells Injection
hUC-MSCs Injection, 3 infusions in total, dosing interval ≥7 days.
其他名称:
  • hUC-MSCs
实验性的:Phase IIa, High-Dose Cohort
Human Umbilical Cord Mesenchymal Stem Cells Injection
hUC-MSCs Injection, 3 infusions in total, dosing interval ≥7 days.
其他名称:
  • hUC-MSCs
安慰剂比较:Phase IIa, Placebo Cohort
Multiple Electrolytes Injection
3 infusions in total, dosing interval ≥7 days

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Phase I : Incidence and number of subjects with treatment-emergent adverse events and serious adverse events.
大体时间:48 weeks
In this Phase I stage, safety is the primary endpoint. Types, frequencies, severities and causal relationships of all adverse events (AEs) and serious adverse events (SAEs) occurring from the first administration of study drug to the end of safety follow-up (48 weeks), assessed in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0; together with the proportion of adverse events judged by the investigator to be related to the study drug.
48 weeks
Phase II :FSH
大体时间:at Week 24 post-treatment
To evaluate the changes from baseline in serum follicle-stimulating hormone (FSH) levels at Week 24 post-treatment.
at Week 24 post-treatment
Phase II :E2
大体时间:at Week 24 post-treatment
To evaluate the changes from baseline in serum festradiol (E2) levels at Week 24 post-treatment.
at Week 24 post-treatment
Phase II :AMH
大体时间:at Week 24 post-treatment
To evaluate the changes from baseline in serum anti-Müllerian hormone (AMH) levels at Week 24 post-treatment.
at Week 24 post-treatment

次要结果测量

结果测量
措施说明
大体时间
Phase I: FSH
大体时间:48 weeks
To evaluate the changes from baseline in serum follicle-stimulating hormone (FSH) levels.
48 weeks
Phase I :E2
大体时间:48 weeks
To evaluate the changes from baseline in serum estradiol (E2) levels
48 weeks
Phase I : AMH
大体时间:48 weeks
To evaluate the changes from baseline in serum anti-Müllerian hormone (AMH) levels.
48 weeks
Phase II: Incidence and number of subjects with treatment-emergent adverse events and serious adverse events.
大体时间:48 weeks
In this Phase II stage, safety is the secondary endpoint. Types, frequencies, severities and causal relationships of all adverse events (AEs) and serious adverse events (SAEs) occurring from the first administration of study drug to the end of safety follow-up (48 weeks), assessed in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0; together with the proportion of adverse events judged by the investigator to be related to the study drug.
48 weeks
Phase I/II: AFC
大体时间:48 weeks
Changes from baseline in antral follicle count (AFC) by transvaginal ultrasound.
48 weeks
Phase I/II: endometrial thickness
大体时间:48 weeks
Changes from baseline in endometrial thickness measured by transvaginal ultrasound.
48 weeks
Phase I/II: menstrual recovery status
大体时间:48 weeks
Menstrual recovery status will be assessed via patient inquiry at each visit.
48 weeks
Phase I/II:Modified Kupperman Index
大体时间:48 weeks

To evaluate the changes in the Modified Kupperman Index from baseline across all post-baseline follow-up visits.

Modified Kupperman Index will be assessed through physician interview.The total score ranges from 0 to 63 points. Total score stratification: >30 points indicates severe symptoms, 16-30 points moderate symptoms, 6-15 points mild symptoms, and <6 points normal status.

48 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年8月3日

初级完成 (估计的)

2028年9月30日

研究完成 (估计的)

2029年8月2日

研究注册日期

首次提交

2026年7月27日

首先提交符合 QC 标准的

2026年8月19日

首次发布 (实际的)

2026年8月20日

研究记录更新

最后更新发布 (实际的)

2026年8月20日

上次提交的符合 QC 标准的更新

2026年8月19日

最后验证

2026年8月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅